台湾2024-2025流感季中期标准剂量灭活疫苗对65岁以上成人预防医疗就诊、住院和死亡的效果
该研究基于台湾多数据库链接的65岁以上成人人群队列,评估2024-2025流感季中期标准剂量三价灭活疫苗效果。结果显示,尽管接种率下降且疫情更严重,疫苗对30天死亡调整VE为71.9%,对ICU入住为70.0%,对住院为58.2%,对门诊就诊为44.8%。结论强调提高老年人接种覆盖率至关重要。
要点
- 疫苗对65岁以上成人30天死亡调整VE为71.9%(95%CI 63.0-78.8)。
- 对流感相关住院调整VE为58.2%(95%CI 52.9-62.9)。
- 对门诊就诊调整VE为44.8%(95%CI 42.4-47.1)。
核心结论
- 尽管接种率下降且疾病负担增加,流感疫苗对65岁以上成人仍高度有效预防严重结局。
- 提高老年人疫苗接种覆盖率对减轻严重季节性流行影响至关重要。
研究设计与样本
- 通过多变量逻辑回归调整年龄、性别和基础合并症,并以索引日期对齐倾向评分匹配作为敏感性分析。
主要发现
- 2024-2025流感季重症病例从1433增至2215,死亡从297增至545,65岁以上成人接种率从53.6%降至48.1%。
- 对30天死亡的调整VE为71.9%(95%CI 63.0-78.8),对ICU入住的调整VE为70.0%(95%CI 62.1-76.2)。
- 对流感相关住院的调整VE为58.2%(95%CI 52.9-62.9),对门诊就诊的调整VE为44.8%(95%CI 42.4-47.1)。
- 倾向评分匹配显示相似趋势但VE估计值普遍较低。
临床怎么用
- 在2024-2025流感季,应优先为65岁以上成人接种标准剂量灭活流感疫苗以预防严重结局。
- 尽管接种率下降,疫苗对死亡和ICU入住等严重结局的保护效果仍较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2024-2025 influenza season in Taiwan was notably more severe than the prior season, with severe cases increasing from 1433 to 2215 and deaths increasing from 297 to 545. Vaccination coverage among adults aged ≥65 years also declined from 53.6% to 48.1%. All government-funded vaccines in the 2024-2025 season were inactivated standard-dose trivalent influenza vaccines. This study aimed to evaluate interim vaccine effectiveness (VE) in this high-burden season. METHODS: Building upon a validated methodological framework from our previous research, we employed a multi-database linkage approach to conduct a population-based cohort study among adults aged ≥65 years in Taiwan from October 1, 2024 through February 15, 2025. We assessed VE against laboratory-confirmed influenza outcomes, adjusting for age, sex, and pre-existing comorbidities through multivariable logistic regression. Index-date aligned propensity score matching was used as sensitivity analysis. RESULTS: Despite a decline in vaccination coverage, the vaccine demonstrated robust protection against severe outcomes. The adjusted VE was 71.9% (95% CI: [63.0-78.8]) against 30-day mortality and 70.0% (95% CI: [62.1-76.2]) against ICU admissions. Protection against influenza-associated hospitalizations was 58.2% (95% CI: [52.9-62.9]), while VE against outpatient visits was 44.8% (95% CI: [42.4-47.1]). Propensity score matching showed similar trend but generally lower VE estimates. CONCLUSIONS: Our findings confirm that the influenza vaccine remains highly effective in preventing severe outcomes, despite the reduced population uptake and increased disease burden. The methodology, consistent with our prior season's analysis, underscores the reliability of these results. We conclude that enhancing vaccination coverage among the elderly is critical to mitigating the impact of severe seasonal epidemics.
引用
- Tsou TP, Huang YT, Lin CY, et al. Influenza vaccine effectiveness against influenza-related medical visits, hospitalization and death among adults aged 65 years and older in Taiwan: interim 2024-2025 season result using standard-dose inactivated influenza vaccine. Vaccine. 2026. PMID: 42810173. doi:10.1016/j.vaccine.2026.129165
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。